Trial Profile
NOTCH 1 Inhibitor Brontictuzumab for Adenoid Cystic Carcinoma Bearing Two Activating NOTCH1 Mutations
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Brontictuzumab (Primary)
- Indications Adenoid cystic carcinoma
- Focus Therapeutic Use
- 18 Jan 2017 Status changed from recruiting to completed.
- 05 Feb 2016 New trial record